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Weakness in the Critically Ill: “Captain of the Men of Death” or Sign of
Disease Severity?
After overcoming numerous complications, critically ill
patients often experience profound muscle weakness. The
subsequent need for prolonged mechanical ventilation, and
their physical disability, can render victory over those conditions
hollow.
In recent years, our understanding of how mechanical
ventilation harms respiratory muscles has advanced
tremendously. Studies have demonstrated a correlation between
duration of mechanical ventilation and diaphragmatic atrophy,
sarcomere injury, decreased diaphragmatic fiber specific force,
and up-regulation of atrophic genes (Atrogin1 and MuRF1)
(1, 2).
Critical illnesses can harm muscles other than respiratory
muscles (3, 4), risking long-term disability and even mortality (5).
Puthucheary and colleagues (3) reported reduction in rectus
femoris area during the first week of critical illness. The decrease
was greater in patients with multiorgan (vs. single-organ) failure,
and in patients fed with greater quantities of protein. The pattern of
intracellular signaling supported increased muscle breakdown and
decreased synthesis. Similar results were reported by Wollersheim
and colleagues (4), who also noted a rapid decrease in myosin
heavy-chain mRNA and increased expression of Atrogin1 and
MuRF1.
In this issue of the Journal (pp. 57–66), Dres and colleagues
(6) extend our knowledge on the prevalence and implications
of muscle weakness in critically ill patients deemed ready for
their first weaning trial. Two-thirds of the 76 patients had
diaphragmatic weakness. One-third had limb weakness. In
contrast to previous reports (7), diaphragmatic weakness was
not associated with sepsis, but was associated with longer
ventilator duration, more frequent weaning failure, and higher
mortality. Limb weakness was associated with longer ventilator
duration and longer hospital stay. Diaphragmatic weakness was
primarily evaluated using twitch tracheal pressure (Ptr,stim)
elicited by magnetic stimulation of the phrenic nerves. Limb
weakness was evaluated with the Medical Research Council
(MRC) score.
On the basis of the new study, can we state with certainty
that respiratory and limb muscles respond differently to critical
illness? This is an important question if we are to tailor the
development of therapies to one muscle group or the other.
Despite known associations between respiratory and limb
muscle weakness (8), it remains biologically plausible for
respiratory and limb muscles to respond differently to critical
illness—the former being more likely than the latter. In rabbits,
controlled mechanical ventilation (CMV) causes injury to
the diaphragm but not to soleus myofibers (9). In patients,
CMV produced diaphragmatic atrophy without impacting
extradiaphragmatic muscles (10). Moreover, CMV up-regulates
Atrogin1 and MuRF1 genes, and induces the autophagy–lysosome
pathway (11). In the quadriceps of these patients, Atrogin1
induction is modest and MuRF1 is absent. Few autophagy-related
genes are expressed above control levels (11).
More controversial is the proposed mechanistic association
between respiratory weakness and weaning failure. Dres and
colleagues (6) found an association between the two, whereas
Laghi and colleagues (12) did not. Can these conflicting results
be reconciled? Dres and colleagues (6) measured Ptr,stim as
a surrogate for transdiaphragmatic twitch pressure (Pdi,stim).
Laghi and colleagues (12) measured Pdi,stim directly (although
Ptr,stim and Pdi,stim are correlated [13, 14]). Of greater importance
than what was measured, is how it was measured and how it was
verified. To obtain accurate twitch pressures, stimulating probes
must be in close proximity to the phrenic nerves (12). Rigorous
strategy is imperative to achieve this goal: one nerve is stimulated
at a time while monitoring electromyography and pressure (13, 14).
Once the probe has been positioned where it elicits the strongest
signal, investigators repeat the process on the other phrenic
nerve. Only then are bilateral stimulations delivered. Verification
to ensure supramaximal stimulation is also required (12) because
low twitch pressures may simply reflect submaximal stimulation
rather than weakness. Watson and colleagues (14) found that
Pdi,stim was 10.8 cm H2O in patients with supramaximal
stimulation and 8.4 cm H2O in patients with submaximal
stimulation. They achieved supramaximality with certainty in
only 75.8% of patients. Dres and colleagues (6) were not able to
test for supramaximality because the ethics committee allowed
them to deliver no more than five bilateral stimulations at a single
stimulating power output (M. Dres and A. Demoule, personal
communication). Thus, we do not know what proportion of
the small twitches signified weakness as opposed to being the
result of insufficient magnetic stimulation.
Another explanation for the contrasting results might be
a type II error in the smaller study by Laghi and colleagues (12).
This seems unlikely considering that in a study of 100 patients,Supported by the Veterans Administration Research Service.
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Yang and Tobin (15) found no difference in maximum
inspiratory airway pressure (MIP) between weaning-failure and
weaning-success patient groups (Figure 1). MIP is a voluntary
maneuver and depends on patient cooperation—as does the more
complex MRC score used by Dres and colleagues (6). Therefore,
if we ignore the MIP data solely because of the need for patient
participation (15), then we should ignore the MRC data of the
newer study as well (6).
Dres and colleagues (6) confirm a possible association between
limb weakness and longer ventilator duration and length of stay
(5, 8). Strategies to improve limb muscle weakness in critically ill
patients, with an aim to decrease hospital length of stay, however,
have produced varying results (16).
There is no question that respiratory muscle weakness is
important, but it is weakness in combination with other equally
important, yet too often ignored factors that impact weaning
outcome. These factors include changes in pulmonary
mechanics during trials of spontaneous breathing and,
possibly, decreased respiratory muscle endurance. The
investigation by Dres and colleagues (6) also points to the need
for studies to identify the mechanisms, if any, linking limb
muscle weakness with ventilator duration and hospital length of
stay. Until we know whether muscle weakness is either the
“captain of the men of death” or a marker of disease severity,
intensivists should strive to limit the duration of mechanical
ventilation and bed rest, while aggressively treating and
preventing sepsis. n
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Figure 1. Maximal inspiratory pressure recorded before a weaning
trial in 60 weaning-success patients (solid symbols) and 40 weaning-failure
patients (open symbols). Maximal inspiratory pressure did not
differ significantly between the groups. The horizontal bars
represent mean values. Data from Reference 15, courtesy of Martin
J. Tobin.
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The Bumpy Road for Noninvasive Ventilation in Acute Respiratory
Distress Syndrome
Coming to an End?
Noninvasive ventilation (NIV) has gained wide acceptance as a
treatment for hypercarbic respiratory failure, but its application
in patients with hypoxemic respiratory failure, with the exception
of those with cardiogenic pulmonary edema or chest trauma, has
been challenging (1). The application for acute respiratory distress
syndrome (ARDS) has even been termed “the final frontier” for
NIV to treat acute respiratory failure (2). Reports on its application
in ARDS are few, and those available have shown high failure rates.
In their 2001 survey on use of NIV to treat acute hypoxemic
respiratory failure, Antonelli and colleagues (3) observed an
NIV failure rate almost fourfold higher for ARDS and pneumonia
than for other forms of hypoxemic acute respiratory failure.
A number of reasons likely explain the challenges of applying
NIV to patients with ARDS. For one, patients with ARDS are
tachypneic and breathe at highminute volumes, making it difficult for
NIV ventilators to keep up and synchronize. Also, the severe
hypoxemia and stiff lungs seen in these patents often necessitate high
levels of positive end-expiratory pressure and pressure support. These
high pressures promote air leaks around the mask, contributing
further to patient–ventilator dyssynchrony and requiring greater
strap tension to control the air leaks, intensifying mask discomfort
and contributing to intolerance. In addition, patients with ARDS
often have underlying processes, such as pneumonia, sepsis, and
multiorgan dysfunction, that may progress to the point where NIV is
no longer sufficient to support oxygenation or stability. If needed
intubation is delayed under these circumstances, unanticipated
respiratory arrest can occur, adding to morbidity and mortality.
Some prior attempts at applying NIV in ARDS have
suggested that there may be a subgroup of patients who benefit.
Antonelli and colleagues (4) described the use of NIV as a “first line
intervention” for ARDS in a prospective cohort of patients,
demonstrating avoidance of intubation in 54% of patients with
ARDS admitted to the intensive care unit (ICU). Those failing
NIV had much higher rates of ventilator-associated pneumonia
and mortality than those who succeeded and could be identified by
having Simplified Acute Physiology Score II greater than 34 and
PaO2/FIO2 less than or equal to 175 after the first hour of NIV.
However, the 54% of patients who succeeded with NIV in the
ICU was calculated without including in the denominator the
two-thirds of patients who were intubated before ICU admission.
Thus, only some 15% of patients in the entire cohort actually
succeeded with NIV therapy.
A subsequent small randomized controlled trial (RCT) on
patients with “early” ARDS (PaO2/FIO2 between 200 and 300) showed
that NIV reduced the need for intubation and the number of organ
failures compared with conventional O2 therapy (5). More recently,
NIV administered via a full face mask was compared with high-flow
nasal oxygen (HFNO) and standard oxygen in a three-way
randomized controlled trial (6) on patients with ARDS (PaO2/FIO2,
300). Although the main outcome, intubation rate, was not different
in the whole cohort, it was significantly lower with HFNO in the
subgroup with PaO2/FIO2 less than 200.
In this issue of the Journal, Bellani and colleagues (pp. 67–77)
report on the use and outcomes of NIV to treat ARDS in LUNG
SAFE (Large Observational Study to Understand the Global
Impact of Severe Acute Respiratory Failure) (7). This study
prospectively collected data over 4 weeks on 2,813 patients with
ARDS (PaO2/FIO2, 300 and new bilateral infiltrates) in 459 ICUs
in 50 countries throughout the world (8). A total of 507 patients
(18%) were managed with NIV on Day 1, and 436 (15.5%)
continued on Day 2. The latter cohort was stratified into mild,
moderate, and severe ARDS subgroups. Rates of NIV use did not
differ between the three subgroups (14.3, 17.3, and 13.2%), whereas
mortality rates did (22.2, 42.3, and 47.1%, respectively). As also
reported by many others, NIV failure was associated with a much
higher mortality than NIV success: 45.4 versus 16.1%, respectively.
A propensity-matched analysis also detected a higher ICU
mortality among patients with a PaO2/FIO2 less than 150 treated
with NIV (36.2%) than in those treated invasively (24.7%).
The study by Bellani and colleagues is one of the largest
cohorts of patients with ARDS treated with NIV yet reported, and
another strength is the systematic prospective data collection on
patients with well-defined ARDS (7). Weaknesses include the
collection of physiologic data only once daily, the lack of data
on interfaces or the duration of use, and the exclusion from
analysis of patients treated with NIV only on Day 1, thus missing
early failures and lowering the reported NIV failure rate.
Furthermore, data on use of HFNO were not collected.
Prior studies on the use of NIV for ARDS have been limited
by the unreliability of ARDS diagnosis. A North American
study using physician diagnosis found no use of NIV for ARDS but
40% use in patients diagnosed with pneumonia, some of whom
probably also had ARDS (9). In the study by Bellani and colleagues
(7), the overall rate of NIV use for ARDS (18%) seems suitably low,
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